The degradation of platelet-activating factor in serum and its discriminative value in atherosclerotic patients

Thrombosis Research

Volumn 52, Issue 6, 1988, Pages 529-540

  Ostermann, G ^a   Lang, A ^a   Holtz, H ^a   Ruhling K ^a   Winkler, L ^b   Till, U ^a  

^a Medizinische Hochschule Erfurt   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Atherosclerosis; Lipoproteins; Platelet Function Tests; Platelet Activating Factor

Indexed keywords

LIPOPROTEIN; THROMBOCYTE ACTIVATING FACTOR;

ATHEROSCLEROSIS; HEART INFARCTION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION;

APOLIPOPROTEINS; ARTERIOSCLEROSIS; BIOLOGICAL MARKERS; HUMAN; LIPIDS; MALE; MYOCARDIAL INFARCTION; PLATELET ACTIVATING FACTOR; PLATELET FUNCTION TESTS; PREDICTIVE VALUE OF TESTS;

EID: 0024205844     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/0049-3848(88)90126-0     Document Type: Article

References (31)

1. Platelet-activating factor: A biologically active phosphoglyceride
2. Pathobiology of platelet-activating factors
3. In vivo metabolism of a new class of biologically active phospolipids: 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine, a platelet activating - hypotensive phospholipid
4. A specific acetylhydrolase for 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (a hypotensive and platelet-activating lipid)
5. Human plasma platelet-activating factor acetylhydrolase
6. Human serum acid-labile factor is an acetylhydrolase that inactivates platelet-activating factor
7. The role of lipoproteins in the degradation of platelet-activating factor
8. Human plasma platelet-activating factor acetylhydrolase. Association with lipoprotein particles and role in the degradation of platelet-activating factor
9. Inactivation of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine by a plasma acetylhydrolase: higher activities in hypertensive rats
10. Plasma from atherosclerotic patients exerts an increased degradation of platelet-activating factor
11. The degradation of platelet-activating factor by high-density lipoprotein in rat plasma
12. The degradation of platelet-activating factor in the plasma of a patient with familial high density lipoprotein deficiency (Tangier disease)
13. Cardiovascular risk factor evaluation of healthy american adults
14. The role of platelets in the development and complications of atherosclerosis
15. Synthese von rac. 1-0-Hexadecyl-2-0-acetyl-glycero-3-phosphocholin (PAF-acether)
16. The diagnosis of ischemic heart pain and intermittent claudication in field surveys
17. Estimation of the concentration of low-density lipoprotein cholesterol in plasma , without use of preparative ultracentrifuge
18. Ein standardisierungsfähiges Verfahren zur quantitativen Bestimmung von Apolipoprotein A-I im Serum mittels Immunturbidimetrie am Spekol-Photometer
19. Ein standardisierungsfähiges Verfahren zur quantitativen Bestimmung von Apolipoprotein B im Serum mittels Immunturbidimetrie am Spekol-Photometer
20. Aggregation of blood platelets by adenosine diphosphate and its reversal
21. Apolipoproteins and lipoproteins of human plasma: significance in health and in disease
22. Platelet activating factor and inflammation in atherogenesis: targets for drug development
23. Hypothesis supporting the primary role of increased platelet activity in atherosclerosis and coronary heart disease
24. Platelet behaviour and vascular disease
25. Detection of prethrombotic states in patients with atherosclerotic lesions
26. Epidemiological characteristics of platelet aggregability
27. Platelet activation in normo- and hyperlipoproteinemias
28. Pharmacology of platelet inhibitors
29. Platelet-inhibitor drugs' role in coronary artery disease
30. Studies on the stimulation of human blood platelets by semisynthetic platelet-activating factor